Mental DisordersMHATNCT03301077
Mental Health in Austrian Teenagers (MHAT)
An observational study of Mental Disorders, run by Medical University of Vienna at 1 site in Austria.
Trial summary
The purpose of the Mental Health in Austrian Teenagers (MHAT) - Study is to collect the first epidemiological data on mental health and psychiatric disorders in a representative sample of Austrian adolescents between 10 and 18 years. Read more about this study
- Who is it for?
- Ages 10 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Mental Disorders
- What is being tested?
- 2-phase epidemiological study (screening, interviews)
- How many people
- 4,000 participants
- Where
- 1 siteAustria
- Study dates
- Jan 2013to Apr 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: general population
Who may be able to join
- adolescents aged 10-18
Who cannot join
- no written informed consent possible due to intelligence or no willingness by parents to include minor
Trial locations and contacts
1 site in 1 country.
Austria1 site
Medical University of Vienna, Dep. of Child and Adolescent Psychiatry
Vienna, 1090
About this study
Official title: The Mental Health in Austrian Teenagers (MHAT) - Study: First Epidemiological Survey
The purpose of the Mental Health in Austrian Teenagers (MHAT) - Study is to collect the first epidemiological data on mental health and psychiatric disorders in a representative sample of Austrian adolescents between 10 and 18 years.
Read the detailed description
Knowing about the prevalence of psychiatric disorders and related risk and protective factors is essential for the development of prevention programs and therapeutic approaches. Up to now, no epidemiological data on prevalence rates of psychiatric disorders and related risk and protective factors based on a representative sample is available for Austrian adolescents.
The aim of the study is to present rates of behavioral, emotional and social problems as well as prevalence rates of mental disorders. Furthermore the investigators want to examine risk factors, protective factors and quality of life in a large sample of adolescents aged 10 to 18 years. A two step design is chosen for this purpose to obtain diagnoses based on the Diagnostic and Statistical Manual of the American Psychiatric Association, Version 5 (DSM-5):
- Phase 1 (screening) is a screening for emotional, behavioral and social problems as well as social and demographic correlates, risk and protective factors and quality of life.
- Phase 2 (interviews) includes structured diagnostic interviews to assess psychiatric diagnoses according to DSM-5 criteria with adolescents above a predefined cut-off score in the screening, and a random sample of adolescents scoring below the cut-off.
- Conditions
- Mental Disorders
- Being tested
- 2-phase epidemiological study (screening, interviews)
- Keywords
- children and adolescents, mental health, epidemiology, psychiatric disorders
- Medical subject headings
- Mental Disorders, Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
2-phase epidemiological study (screening, interviews)Other
first phase is the screening phase, second phase is the interview phase
| Study group | Role | What they receive |
|---|---|---|
| General population | recruited from schools and other institutions like job-centers or child and adolescent psychiatries Receives: Other: 2-phase epidemiological study (screening, interviews) |
What is being measured
The primary outcome is the main question the study is designed to answer.
psychiatric problems (diagnoses based on the Diagnostic and Statistical Manual of the American Psychiatric Association, Version 5 (DSM-5)
Screening and interview
Measured: 12 months
Secondary outcomes (3)
rates of behavioral, emotional and social problems (representation of data collected at interview)
YSR (Youth Self Report) questionnaire
Measured: 12 months
psychiatric disorder related risks and protective factors (representation of data collected at interviews)
Kinder-DIPS (Diagnostisches Interview psychischer Störungen) interview
Measured: 12 months
quality of life (total score, self-perception, parent relation & home life, social support & peers, school environment and bullying)
KIDSCREEN (Kidscreen) questionnaire
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2017
- Study startJan 2013
- Primary completionApr 2015
- Study completionApr 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mental DisordersStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 4,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Collaborators
- Ludwig Boltzmann Institut Health Promotion Research, Pharmig - Gesundheitsziele aus dem Rahmen-Pharmavertrag
- Responsible party
- Principal investigator, Dr. Andreas Karwautz, Medical University of Vienna
- Investigators
- Andreas Karwautz, MD, Prof, Study director, Medical University of ViennaWolfgang Dür, Phd, Prof, Study director, Ludwig Boltzmann Institute LBIHPR
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03301077
- Sponsor's protocol ID
- FA765A0303
- Acronym
- MHAT
- Status last verified
- Mar 2019
- First submitted
- 21 Jul 2014
- Last updated
- 7 Mar 2019
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Mental Health in Austrian Teenagers (MHAT) - Study: First Epidemiological Survey
- ClinicalTrials.gov ID
- NCT03301077
- Acronym / sponsor ID
- MHAT / FA765A0303
- Conditions
- Mental Disorders
- Keywords
- children and adolescents, mental health, epidemiology, psychiatric disorders
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4,000 participants (actual)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Collaborators
- Ludwig Boltzmann Institut Health Promotion Research, Pharmig - Gesundheitsziele aus dem Rahmen-Pharmavertrag
- Study start
- Jan 2013
- Primary completion
- Apr 2015 (actual)
- Study completion
- Apr 2015 (actual)
- First posted
- 4 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the Mental Health in Austrian Teenagers (MHAT) - Study is to collect the first epidemiological data on mental health and psychiatric disorders in a representative sample of Austrian adolescents between 10 and 18 years.
Detailed description
Knowing about the prevalence of psychiatric disorders and related risk and protective factors is essential for the development of prevention programs and therapeutic approaches. Up to now, no epidemiological data on prevalence rates of psychiatric disorders and related risk and protective factors based on a representative sample is available for Austrian adolescents.
The aim of the study is to present rates of behavioral, emotional and social problems as well as prevalence rates of mental disorders. Furthermore the investigators want to examine risk factors, protective factors and quality of life in a large sample of adolescents aged 10 to 18 years. A two step design is chosen for this purpose to obtain diagnoses based on the Diagnostic and Statistical Manual of the American Psychiatric Association, Version 5 (DSM-5):
- Phase 1 (screening) is a screening for emotional, behavioral and social problems as well as social and demographic correlates, risk and protective factors and quality of life.
- Phase 2 (interviews) includes structured diagnostic interviews to assess psychiatric diagnoses according to DSM-5 criteria with adolescents above a predefined cut-off score in the screening, and a random sample of adolescents scoring below the cut-off.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| General population | – | Other: 2-phase epidemiological study (screening, interviews)recruited from schools and other institutions like job-centers or child and adolescent psychiatries |
Who may qualify
- Ages
- 10 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- general population
Key inclusion criteria (1 listed)
- adolescents aged 10-18
Key exclusion criteria (1 listed)
- no written informed consent possible due to intelligence or no willingness by parents to include minor
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 2-phase epidemiological study (screening, interviews)first phase is the screening phase, second phase is the interview phase | Other | General population |
Primary outcome
psychiatric problems (diagnoses based on the Diagnostic and Statistical Manual of the American Psychiatric Association, Version 5 (DSM-5)
Time frame: 12 months
Screening and interview
3 secondary outcomes
rates of behavioral, emotional and social problems (representation of data collected at interview)
Time frame: 12 months
psychiatric disorder related risks and protective factors (representation of data collected at interviews)
Time frame: 12 months
quality of life (total score, self-perception, parent relation & home life, social support & peers, school environment and bullying)
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2019.
- Related InfoLink provided by the sponsor.
Related trials for Mental Disorders
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andreas Karwautz, MD, Prof study director
Medical University of Vienna
Wolfgang Dür, Phd, Prof study director
Ludwig Boltzmann Institute LBIHPR
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mental Disorders, run by Medical University of Vienna at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
psychiatric problems (diagnoses based on the Diagnostic and Statistical Manual of the American Psychiatric Association, Version 5 (DSM-5) (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2019.